The innovative dental application Prevora, developed by Mississauga's
CHX Technologies Inc., has been shown in trials to reduce cavities in uninsured adults and those using state dental services by 60 per cent. Already approved for sale in Canada and Ireland, the company reached another marketing milestone when
Prevora was recently approved for sale in the UK by the European Medicines Agency. The organization also allows for the product to be recognized in other European Union member states.
Prevora is a topical application that coats the tooth and releases high-strength chlorhexidine into the tooth over the long term, inhibiting the growth of bacteria that cause tooth decay. The company reports that the UK is a promising market for their product, as tooth decay is among the top three chronic diseases in older adults.
A statement sent by company President Ross Perry says the company will seek US approval for the treatment soon. He says that the recent news is a boon to the company's progress. "Prevora will reduce the burden of tooth decay amongst those high-risk
dental patients who experience most of this disease in a family dental
practice. This positive opinion by the EMA is an important step to
Prevora's approval in European markets."
Writer: Edward Keenan
Source: Ross Perry, President, CHX Technologies Inc.